Healthtech Solutions Inc. Sells Patents and World Reach Companies in $30 Million Deal with Papyrus
Healthtech Solutions Inc., a Utah-based corporation, has announced the completion of significant transactions involving the sale of its patent assets and corporate entities. On June 5, 2025, Healthtech Solutions entered into a Patent Purchase Agreement to sell one patent and four patent applications related to wound care products derived from placental membranes, including DermaBind-TL and DermaBind-FM, to Papyrus Therapeutic LLC for $5,000,000. Additionally, the company finalized the sale of its majority-owned World Reach Companies to Papyrus Distribution LLC for $25,000,000. The deal includes provisions for the payment of $10,000,000 through secured promissory notes. The transaction was completed on June 6, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Healthtech Solutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-004487), on June 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.